Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE)

In RCT (n=333), proportions of patients with clinical response at test-of-cure visit, 7–10 days after last infusion of study therapy, were similar with ceftazidime-avibactam or best available therapy (91% each group). An adverse event was reported in 31% and 39%, respectively.

According to a commentary, the REPRISE study provides strong evidence that long-existing antibiotics like ceftazidime could become therapeutically effective again, if used in combination with a resistance-breaking element, such as in combination with a novel β-lactamase inhibitor (avibactam). It notes that since consumption of antibiotics and development of resistance seem to be strongly correlated, the introduction of this protected ceftazidime could also help to reduce the excessive use of carbapenems, the last-resort antibiotics, which has resulted in a dramatic increase in resistance in some parts of the world.

 

A licensing application for ceftazidime-avibactam was filed in EU in June 2015.